Sverre E. Kjeldsen

TL;DR: The influence of blood pressure at 600 kpm/min was so strong that the predictive value of resting casual blood pressures became nonsignificant when these were analyzed as continuous variables also including exercise blood pressure as a covariate.

TL;DR: Absence of in-treatment ECG LVhypertrophy is associated with reduced risk of SCD independently of treatment modality, blood pressure reduction, prevalent coronary heart disease, and other cardiovascular risk factors in hypertensive patients with LV hypertrophy.

TL;DR: It seems some classes are superior to others in the prevention of new-onset atrial fibrillation and prevention of stroke and new classes of anticoagulants that do not require international normalized ratio monitoring have been introduced with promising results.

TL;DR: The data suggest that adjusted drug treatment has superior BP lowering effects compared with RDN in patients with true TRH, and Ambulatory BPs changed in parallel to office BPs.

TL;DR: The Systolic Blood Pressure Intervention Trial (SPRINT) enrolled 9361 participants aged ≥50 years in expert medical centers and clinical practices throughout the United States and had reduced rates of the composite primary outcome that included myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes by 25% and the risk of death from all causes by 27%, when compared with the target SBP of <140 mm Hg.